CAS 55096-26-9|Nalmefene
| Common Name | Nalmefene | ||
|---|---|---|---|
| CAS Number | 55096-26-9 | Molecular Weight | 339.43 |
| Density | / | Boiling Point | / |
| Molecular Formula | C21H25NO3 | Melting Point | 188 - 190ºC |
| MSDS | ChineseUSA | Flash Point | / |
| Symbol | GHS07 | Signal Word | Warning |
Names
| Name | (4R,4aS,7aS,12bS)-3-(cyclopropylmethyl)-7-methylidene-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol |
|---|---|
| Synonym | More Synonyms |
Nalmefene BiologicalActivity
| Description | Nalmefene is a long acting opioid (MOR and DOR antagonist), and a partial KOR agonist. Nalmefene is used for opioid overdose and alcohol dependence[1]. |
|---|---|
| Related Catalog | Signaling Pathways >>GPCR/G Protein >>Opioid ReceptorSignaling Pathways >>Neuronal Signaling >>Opioid ReceptorResearch Areas >>Neurological Disease |
| Target | MOR, DOR, KOR[1] |
| References | [1]. Wang DS, et al. Nalmefene: a long-acting opioid antagonist. Clinical applications in emergency medicine. J Emerg Med. 1998 May-Jun;16(3):471-5. [2]. Mann K, et al. Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. Eur Neuropsychopharmacol. 2016 Dec;26(12):1941-1949. |
Chemical & Physical Properties
| Melting Point | 188 - 190ºC |
|---|---|
| Molecular Formula | C21H25NO3 |
| Molecular Weight | 339.43 |
| Exact Mass | 339.18300 |
| PSA | 52.93000 |
| LogP | 2.45040 |
| InChIKey | WJBLNOPPDWQMCH-MBPVOVBZSA-N |
| SMILES | C=C1CCC2(O)C3Cc4ccc(O)c5c4C2(CCN3CC2CC2)C1O5 |
| Storage condition | 2-8°C |
Safety Information
| Symbol | GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi |
| Risk Phrases | 36/37/38 |
| Safety Phrases | S26-S36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
Articles39
More Articles| Treatment of alcohol dependence: recent progress and reduction of consumption. Minerva Med. 105(6) , 447-66, (2014) Alcohol dependence (AD) is a major public health problem. Currently, three drugs for the treatment of AD have been approved by both the European Medicines Agency (EMA) and the Food and Drug Administra... | |
| Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA 311(18) , 1889-900, (2014) Alcohol use disorders cause substantial morbidity and early mortality yet remain greatly undertreated. Medications are considerably underused.To conduct a systematic review and meta-analysis of the be... | |
| In vivo characterization of the opioid antagonist nalmefene in mice. Life Sci. 86(15-16) , 624-30, (2010) The current study assessed the in vivo antagonist properties of nalmefene using procedures previously used to characterize the opioid antagonists naloxone, naltrexone, 6beta-naltrexol and nalbuphine.I... |
Synonyms
| Arthene |
| Nalmefenum |
| Nalmetrenum |
| Alcofene |
| Nalmetreno |
| 6-desoxy-6-methylenenaltrexone |
| Nalmetrene |
| Revex |
| nalmefene |
| Cervene |
